Literature DB >> 16018979

Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?

Jacquelien J G Hillebrand1, Annemarie A van Elburg, Martien J H Kas, Herman van Engeland, Roger A H Adan.   

Abstract

BACKGROUND: Anorexia nervosa (AN) patients often show extreme hypophagia and excessive physical activity. Activity-based anorexia (ABA) is considered an animal model of AN and mimics food restriction and hyperactivity in rats. This study investigated whether treatment with olanzapine (Zyprexa) reduces the development of ABA in rats. The effect of olanzapine treatment in AN patients was also evaluated in a small open-label study.
METHODS: Rats were chronically (1 week) infused with olanzapine (7.5 mg/kg) and exposed to the ABA model or ad libitum feeding. Hyperactive AN patients were followed for up to 3 months of olanzapine treatment (5 mg/kg).
RESULTS: Olanzapine treatment reduced development of ABA in rats by reducing running wheel activity, starvation-induced hypothermia and activation of the hypothalamus-pituitary-adrenal axis. Olanzapine treatment reduced activity levels of AN patients compared with untreated AN patients, without affecting body weight and plasma leptin levels.
CONCLUSIONS: Olanzapine treatment reduced wheel running and thereby diminished development of ABA in rats. Olanzapine treatment also reduced physical activity in hyperactive AN patients in a small open-label study. These data support the need for controlled studies investigating the putative beneficial effects of olanzapine treatment in AN patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16018979     DOI: 10.1016/j.biopsych.2005.04.008

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  21 in total

Review 1.  Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials.

Authors:  Timothy D Brewerton
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 2.  The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Authors:  Guido K W Frank; Megan E Shott
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

3.  Dopaminergic activity and exercise behavior in anorexia nervosa.

Authors:  Sasha Gorrell; Anne G E Collins; Daniel Le Grange; Tony T Yang
Journal:  OBM Neurobiol       Date:  2020-03-23

Review 4.  Interacting Neural Processes of Feeding, Hyperactivity, Stress, Reward, and the Utility of the Activity-Based Anorexia Model of Anorexia Nervosa.

Authors:  Rachel A Ross; Yael Mandelblat-Cerf; Anne M J Verstegen
Journal:  Harv Rev Psychiatry       Date:  2016 Nov/Dec       Impact factor: 3.732

Review 5.  Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans.

Authors:  M A van Gestel; E Kostrzewa; R A H Adan; S K Janhunen
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 6.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

7.  Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.

Authors:  Stephanie J Klenotich; Mariel P Seiglie; Matthew S McMurray; Jamie D Roitman; Daniel Le Grange; Priya Dugad; Stephanie C Dulawa
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

8.  The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia.

Authors:  Aaron N A Verty; Megan J Evetts; Geraldine J Crouch; Iain S McGregor; Aneta Stefanidis; Brian J Oldfield
Journal:  Neuropsychopharmacology       Date:  2011-03-16       Impact factor: 7.853

9.  Adolescent female C57BL/6 mice with vulnerability to activity-based anorexia exhibit weak inhibitory input onto hippocampal CA1 pyramidal cells.

Authors:  T G Chowdhury; G S Wable; N A Sabaliauskas; C Aoki
Journal:  Neuroscience       Date:  2013-03-21       Impact factor: 3.590

10.  The impact of hyperactivity and leptin on recovery from anorexia nervosa.

Authors:  A A van Elburg; M J H Kas; J J G Hillebrand; R J C Eijkemans; H van Engeland
Journal:  J Neural Transm (Vienna)       Date:  2007-05-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.